| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/11/2007 | WO2006101954A3 Interstitial cystitis treatment |
| 01/11/2007 | WO2006099193A3 Chromen-4-one inhibitors of anti-apoptotic bcl-2 family members and the uses thereof |
| 01/11/2007 | WO2006095173A3 Medical uses of 39-desmethoxyrapamycin and analogues thereof |
| 01/11/2007 | WO2006094209A3 N-benzimidazolylalkyl-substituted amide sirtuin modulators |
| 01/11/2007 | WO2006089651A3 Trofosfamide-containing film-coated tablets and method for the production thereof |
| 01/11/2007 | WO2006089053A3 Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives |
| 01/11/2007 | WO2006089038A3 Insecticidal tetrahydroindenopyridine derivatives |
| 01/11/2007 | WO2006088720A3 9-substituted tetracyclines |
| 01/11/2007 | WO2006088483A3 Compositions and methods for inhibiting the synthesis or expression of mmp-1 |
| 01/11/2007 | WO2006086681A3 Methods of inhibiting smooth muscle cell migration and proliferation |
| 01/11/2007 | WO2006086108A3 Use of inhibitors of soluble epoxide hydrolase to synergize activity of cox and 5-lox inhibitors |
| 01/11/2007 | WO2006086012A3 Antibiotic compound |
| 01/11/2007 | WO2006085033A3 Pharmaceutical compositions for the treatment of prostate cancer |
| 01/11/2007 | WO2006084369A9 Diamine calcium channel blockers |
| 01/11/2007 | WO2006084233A3 Modulation of endogenous aicar levels for the treatment of diabetes and obesity |
| 01/11/2007 | WO2006083979B1 Local treatment of neurofibromas |
| 01/11/2007 | WO2006083692A3 Methods of identifying modulators of bromodomains |
| 01/11/2007 | WO2006081445A3 Treatment of metastasized tumors |
| 01/11/2007 | WO2006078886A3 Compounds and compositions as wnt signaling pathway modulators |
| 01/11/2007 | WO2006078875A3 A method for treating neurologic diseases |
| 01/11/2007 | WO2006076370A3 Substituted cyclopentanes or cyclopentanones for the treatment of ocular hypertensive conditions |
| 01/11/2007 | WO2006074962A3 Erythromycin derivatives as antibacterial agents |
| 01/11/2007 | WO2006074428A3 Cxcr4 antagonists for the treatment of medical disorders |
| 01/11/2007 | WO2006074192A3 Treatment of inflammatory disorders |
| 01/11/2007 | WO2006072792A3 Compounds which bind to the active site of protein kinase enzymes |
| 01/11/2007 | WO2006060548A3 Novel dermatological composition using bio-activating organocatalysts |
| 01/11/2007 | WO2006059152A3 Pharmaceutical formulations |
| 01/11/2007 | WO2006052798A3 Method of treating pathological blushing |
| 01/11/2007 | WO2006041592A3 Large-scale manufacturing process for the production of pharmaceutical compositions |
| 01/11/2007 | WO2006032342A3 Carbonyl compound-containing drug and the use thereof |
| 01/11/2007 | WO2006020179A3 Oligomeric ketone compounds |
| 01/11/2007 | WO2006014359A3 Compounds useful for inhibiting chk1 |
| 01/11/2007 | WO2006009734A8 Gonadotropin releasing hormone receptor antagonists |
| 01/11/2007 | WO2005116023A8 3- {4- (pyridin-3-yl) phenyl} -5- (1h-1, 2, 3-triazol-1-ylmethyl) -1, 3-oxazolidin-2-ones as antibacterial agents |
| 01/11/2007 | WO2005107747A3 Diindolymethane formulations for the treatment of leiomyomas |
| 01/11/2007 | WO2005099665A3 Imroved formulations of 6-mercaptopurine |
| 01/11/2007 | WO2005092934A8 Orthoester-protected polyols for low voc coatings |
| 01/11/2007 | WO2005079270A3 2-substituted and 4-substituted aryl nitrone compouds |
| 01/11/2007 | WO2005025620A3 Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents |
| 01/11/2007 | WO2003083057A3 Adipocytes and uses thereof |
| 01/11/2007 | US20070011754 Lysosomal proteins produced in the milk of transgenic animals |
| 01/11/2007 | US20070010871 Energetically-controlled delivery of biologically active material from an implanted medical device |
| 01/11/2007 | US20070010677 Process for production of piperidine derivatives |
| 01/11/2007 | US20070010676 Stereospecific enrichment of heterocyclic enantiomers |
| 01/11/2007 | US20070010669 Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof |
| 01/11/2007 | US20070010586 Enhanced tuburculocidal activity and decreased fumes from glutaraldehyde disinfectant using acetate salts and alcohol |
| 01/11/2007 | US20070010585 Compounds having strong beta -galactosidase inhibitory activity or beta -glucosidase inhibitory activity; excellent solubility; pseudo-sugar; excellent treatment or prevention of glycolipid metabolic disorders |
| 01/11/2007 | US20070010584 Compositions and methods for orthostatic intolerance |
| 01/11/2007 | US20070010583 Methods and compositions for reducing blood homocysteine levels |
| 01/11/2007 | US20070010582 Topical administering; skin disorders |
| 01/11/2007 | US20070010581 Use of 2,5-dihydroxybenzenesulfonic compounds for the treatment of disorders based on an impairment of no production and/or of regulation of edhf function |
| 01/11/2007 | US20070010580 Formulation for chemical peeling |
| 01/11/2007 | US20070010578 controlling the duration of the depolarization and repolarization of the cardiac ventricle comprising administering 2-(2-chlorophenyl)-2-hydroxyethyl] carbamate or enantiomeric mixtures; treatment of Long QT Syndrome |
| 01/11/2007 | US20070010577 Administering an emulsion of a nanoparticulate carrier containing an alpha v beta 3 integrin targeting ligand and fumagillin, TNP 470 or rapamycin that are coupled through colocalization in the nanoparticles; the antiangiogenic agent is effective at a dosage at least 56,000 fold lower than the free drug |
| 01/11/2007 | US20070010576 performing an intramolecular cyclization of tetrahydrofuran-allenol derivatives in the presence of alcohol compound, transitional metal catalyst and carbon monoxide |
| 01/11/2007 | US20070010575 Intracorporeal medicaments for photodynamic treatment of disease |
| 01/11/2007 | US20070010574 Use of a trpm8-activating substance for the treatment of tumours |
| 01/11/2007 | US20070010573 reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity |
| 01/11/2007 | US20070010572 Reaction of benzyl (2S)-2,3,4,5,6,7-hexahydro-1H-indole-2-carboxylate with triethylamine and then (2S)-2-[(tert-butoxycarbonyl)amino]propionyl chloride and reaction of product with ethyl 2-oxopentanoate and hydrogenation using platinum on carbon catalyst |
| 01/11/2007 | US20070010571 Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use |
| 01/11/2007 | US20070010570 Medical Compositions for Intravesical Treatment of Bladder Cancer |
| 01/11/2007 | US20070010569 4-Methyl-5-(2-oxo-1,2-dihydroindol-3- ylidenemethyl)-1H-pyrrole-2- carboxylic acid; cancer |
| 01/11/2007 | US20070010568 highly potent; side effect reduction; for the treatment of diseases of the respiratory, urinary and gastrointestinal systems; 3-(2-Methoxy-5-methylphenyl)-3-phenylpropionic acid-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-carbamoyl)methyl ester; condensation; deprotection |
| 01/11/2007 | US20070010567 microbiocide for latex, paint, coating, cosmetic or personal care formulations; side effect reduction; homogeneous solution at low temperatures for an extended period of time |
| 01/11/2007 | US20070010566 Thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents |
| 01/11/2007 | US20070010565 New thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents |
| 01/11/2007 | US20070010564 Antiproliferative agent; antitumor, anticancer; 2-Thiophen-2-yl-ethenesulfonic acid benzoylamides; reaction of the halogenated heteroaryl ring with ethenesulfonic acid (1,1,3,3-tetramethyl-butyl)-amide, dealkylation, then benzoylation |
| 01/11/2007 | US20070010563 Novel methods for the treatment of inflammatory diseases |
| 01/11/2007 | US20070010562 Nr1h4 nuclear receptor binding compounds |
| 01/11/2007 | US20070010561 Prenylation inhibitors and methods of their synthesis and use |
| 01/11/2007 | US20070010560 Benzimidazole derivatives as raf kinase inhibitors |
| 01/11/2007 | US20070010559 Indole derivatives for use as chemical uncoupler |
| 01/11/2007 | US20070010558 Opioid receptor antagonists |
| 01/11/2007 | US20070010557 Novel amides useful for treating pain |
| 01/11/2007 | US20070010556 Thiophene derivatives as chk 1 inhibitors |
| 01/11/2007 | US20070010555 Indazole having analgesic activity |
| 01/11/2007 | US20070010554 Aryl substituted pyridines and the use thereof |
| 01/11/2007 | US20070010553 New use |
| 01/11/2007 | US20070010552 Fluorinated heterocyclic compounds and methods of synthesis |
| 01/11/2007 | US20070010551 Quinoline derivatives as neutrophil elastase inhibitors and their use |
| 01/11/2007 | US20070010550 Scopolamine to Reduce or Eliminate Hot Flashes, Night Sweats, and Insomnia |
| 01/11/2007 | US20070010549 Imidazo(4,5-b)pyridine-derivatives as inducible no-synthase inhibitors |
| 01/11/2007 | US20070010548 Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof |
| 01/11/2007 | US20070010547 Method for modulating gene expression in epithelial cells |
| 01/11/2007 | US20070010546 Method for enhancing epithelial cell proliferation and uses thereof |
| 01/11/2007 | US20070010545 Solid forms of a chemokine receptor antagonist and methods of use thereof |
| 01/11/2007 | US20070010544 e.g. 4,7,7-trimethyl-7, 12,12a,6a-tetrahydrochromano[4,3-b]quinoline; increasing cellular ATP binding cassette transporter ABCA1 production ; reduces cholesterol deposition in coronary arteries; coronary artery diseases, dyslipidiemias and metabolic syndrome |
| 01/11/2007 | US20070010543 Compositions and methods for treating gastrointestinal hypomotility and associated disorders |
| 01/11/2007 | US20070010542 Therapeutic or prophylactic agent for acid-related diseases, having an excellent inhibitory effect against gastric acid secretion, an excellent effect of maintaining the inhibitory effect against gastric acid secretion, thereby maintaining intragastric pH high for a long time, bactericidal agent |
| 01/11/2007 | US20070010541 Methods for treating vascular diseases |
| 01/11/2007 | US20070010540 ;Crystal proteins; antineoplastic agents for colon or breast carcinoma; diamino-pyrimidine Colony stimulating factors (cFMS) inhibitors like 5-{3-methoxy-4-[(4-methoxybenzyl)oxy]benzyl}pyrimidine-2,4-diamine; drug screening |
| 01/11/2007 | US20070010539 Ethyl-1'-[(2S)-2-hydroxy-2-phenylethyl]-6'-oxo-8'-(pyridin-4-yl)-1',3',4',6'-tetrahydro-1H-spiro[piperidine-4,2'-pyrimido[1,2-a]pyrimidine]-1-carbox; glycogen synthase kinase-3 beta, amyloid precursor protein, tau protein hyperphosphorylation inhibitor; neurodegenerative disease, type II diabetes |
| 01/11/2007 | US20070010538 Inhibition of pathogenic processes related to tissue trauma |
| 01/11/2007 | US20070010537 Fused pyramidine derivative and use thereof |
| 01/11/2007 | US20070010536 Selectively inducing terminal differentiation of neoplastic cells; antiproliferative agents; antineoplastic agents; antitumor agents; melanomes; acute leukemia, multiple myeloma; carcinomas; neuroblastoma; N-t-butoxycarbonyl- omega -methyl - alpha -aminosuberateanilide |
| 01/11/2007 | US20070010535 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological atates |
| 01/11/2007 | US20070010534 Novel compounds |
| 01/11/2007 | US20070010533 Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (bvdv) infection and hepatitis c virus (hcv) infection |
| 01/11/2007 | US20070010531 Substituted pyrazole compounds |
| 01/11/2007 | US20070010530 Inhibiting the proteolytic activity of cathepsin S; 1-[4-(5-Chloro-1H-indol-3-yl)-piperazine-1-yl]-3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propan-2-ol; antiarthritic agent; autoimmune disease: lupus, rheumatoid arthritis, and asthma |